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It has been reported that cellular prion protein (PrPc) is enriched in caveolae or caveolae-like domains with caveolin-1 (Cav-1)
participating to signal transduction events by Fyn kinase recruitment. By using the Glutathione-S-transferase (GST)-fusion pro-
teins assay, we observed that PrPc strongly interacts in vitro with Cav-1. Thus, we ascertained the PrPc caveolar localization in a
hypothalamic neuronal cell line (GN11), by confocal microscopy analysis, ﬂotation on density gradient, and coimmunoprecipita-
tion experiments. Following the anti-PrPc antibody-mediated stimulation of live GN11 cells, we observed that PrPc clustered on
plasma membrane domains rich in Cav-1 in which Fyn kinase converged to be activated. After these events, a signaling cascade
through p42/44 MAP kinase (Erk 1/2) was triggered, suggesting that following translocations from rafts to caveolae or caveolae-
like domains PrPc could interact with Cav-1 and induce signal transduction events.
Copyright © 2006 Mattia Toni et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Multiproteic caveolar complexes represent a sophisticated
membrane organization involved in signal transduction.
Their eﬃciency is linked to the insertion of proteins in a
restricted membrane area (50–100nm) where the genera-
tion of a signal has a vectorial and oriented characteristic
and allows the recruitment of low-abundance proteins in
order to activate signaling pathways which, in neural cells,
seem to control diﬀerentiation and cell survival [1–4]. Cave-
olae are a subclass of membrane microdomains distinguish-
able by their shape (they are ﬂask-like invaginations) and by
the presence of membrane proteins of the caveolin family.
Caveolin-1 (Cav-1) is a small 22 kDa highly versatile pro-
tein capable of organizing several caveolar functions. Lisanti
and coworkers have precisely mapped the molecule deﬁning
two sites involved in the binding of caveolar constituents: a
hydrophobic region (aa 82–101) called scaﬀolding domain
(SD),andamorehydrophilicmotifpresentintheC-terminal
region indicated as CID motif [5].
Cellular prion protein (PrPc) is a secreted protein an-
chored to cell surface via a GPI anchor and believed to func-
tionasacellsurfacereceptor[6]orligand[7,8].PrPcischar-
acterized by an amino terminal unstructured highly ﬂexible
region characterized by the presence of multiple octapeptide
repeats highly conserved during evolution that are bind-
ing sites for copper ions [9]. In neuroblastoma cells lacking
caveolae, PrPc has been isolated in detergent-insoluble com-
plexes denominated “caveolae-like domains” (CLDs) and it
has been hypothesized that PrPc conversion in its patholog-
ical conformer PrP scrapie (PrPsc) occurs in this subcellu-
lar compartment [10, 11]. Recent data obtained by electron
microscopy in CHO cells clearly conﬁrmed that PrPc is in-
ternalized by caveolae [12]. Moreover, it has been observed
that Cav-1 is coimmunoprecipitated by using PrPc antibody
and that Cav-1 mediates the recruitment and the activation
of Fyn kinase after anti-PrPc antibody-mediated stimulation
[13, 14]. Evidence supporting a role of PrPc in regulating cell
proliferation, diﬀerentiation, and survival has been collected
[15].
Fyn kinase is a member of Src family kinase involved in
signal transduction events. It has been reported that Fyn ki-
nase during signal transduction events is noncovalently as-
sociated with glycosylphosphatidylinositol (GPI)-anchored
proteins [16–18] and that Fyn kinase, after the palmitoyla-
tion of its Cys3, is included in caveolae [19]. Moreover, it has
been shown that, following antibody-mediated cross linking,
GPI-anchored proteins lead to signal transduction events in
T cells, B cells, monocytes, and granulocytes [20] and that
are sequestered in caveolae [21].2 Journal of Biomedicine and Biotechnology
Erk 1/2 has been intensively studied in neurons because
of its participation to hippocampal mechanisms leading to
learning and memory consolidation [22]. Caveolae play an
important role in Erk 1/2 regulation. In fact, it has been re-
ported that Erk 1/2 is compartmentalized within caveolae
[23, 24] and that Cav-1 can inhibit Erk 1/2 activity [25–29].
Interestingly, it has been reported that a reciprocal relation-
ship between Cav-1 and Erk 1/2 as activation of the p42/44
MAP kinase cascade causes the downregulation of Cav-1 ex-
pression[30].Moreover,theroleofPrPcinErk1/2activation
has been analyzed [14, 31, 32].
Findings reported here demonstrate that PrPc and Cav-1
interact in vitro and colocalize in GN11 cells,a hypothalamic
neuronalcelllinethathighlyexpressesCav-1gene.Moreover,
we examined the role played by caveolae and PrPc in signal
transduction by transfecting GN11 cells with a novel PrPc-
expressing vector showing a high transfection eﬃciency, in
order to compare Fyn and Erk 1/2 kinases activity in wild-
type and PrPc-overexpressing cells. Our results highlight the
key role of caveolae as sophisticated microenvironments in
whichPrPcclusterstogeneratesignaltransductionpathways.
MATERIAL AND METHODS
Antibodiesused
Anti-PrPc monoclonal antibody (Mab) 3F4 (western Blot
(WB) 1 : 3000; Immunoﬂuorescence (IF) 1 : 50; DakoCy-
tomation,Denmark);antimurinePrP-Nterminuspolyclonal
antiserum Ab ·Tg (kindly provided by Dr T. Yokoyama,
Japan [33]), anti-human PrP-C terminus goat polyclonal an-
tibody (Pab) C-20 (Santa Cruz Biotechnology, USA); anti-
human recombinant Doppel protein (hurDpl) Pab Q55 (WB
1 : 100); Mab Dpl 79 (kindly provided by Dr J. Grassi, Com-
missariat a l’Energie Atomique/Saclay, France); anti-Cav-1
Pab (WB 1 : 5000; IF 1 : 100; BD Biosciences, USA), anti-
Cav-1 FITC-conjugated antibody (IF 1 : 50; Santa Cruz
Biotechnology, USA), antihaemagglutinin (HA)-epitope Pab
(BD Biosciences, USA); anti-Fyn kinase Pab (IF 1 : 100;
Santa Cruz Biotechnology, USA), anti-phospho-Src family
(Tyr416) Pab (IF 1 : 200; Cell Signaling, USA), anti-phospho
Erk1/2 Mab (WB 1 : 1000; Cell Signaling, USA); anti- β-
actin Pab (WB 1 : 1200; Sigma, USA), secondary anti-mouse
FITC- or Cy3-conjugated antibodies (IF 1 : 50, Sigma, USA);
anti-rabbit Cy5-conjugated donkey Ab F(ab’)2 fragment (IF
1 : 50, Jackson, USA); anti-mouse and anti-rabbit secondary
Horseradish Peroxidase (HRP)-conjugated antibodies (WB
1 : 1000, Santa Cruz Biotechnology, USA). Antibodies were
diluted in PBS-BSA 3% or in 5% nonfat milk powder-TBS-
TWEEN buﬀer, for IF or WB experiments, respectively. For
live cells stimulation the antibodies were used at the dilution
of 1 : 100 in DMEM supplemented with 10% FCS.
Plasmidconstruction
Haemagglutinin-taggedPrP(PrP-HA)plasmidwasprepared
as follows: the coding region (23–254) of mouse PrPc was
prepared, as described in Negro et al [34], with two Mets
at positions 108 and 111 (L108M, V111M) to provide the
epitope speciﬁc for commercial Mab 3F4. Then, the cod-
ing region was cloned into the mammalian expression vec-
tor pRK7HA (a kind gift of Dr Elisabetta Ciani, Bologna,
Italy), downstream of the HA-tag sequence, between BamHI
and EcoRI restriction sites. The region coding for mouse PrP
signal peptide (1–22) was then cloned into the recombinant
vector, upstream of the HA epitope sequence, between AgeI
and HindIII restriction sites. Expression vector for human
Dpl was prepared as in [34].
GST-bindingassay
Recombinantfull-lengthformsofmorPrP(23–231)andhur-
Dpl (28–152) were generated in, and puriﬁed from, Es-
cherichia coli as described in Negro et al [34]. To provide the
epitopespeciﬁcforMab3F4,morPrPcarriedtwoMetsatpo-
sitions 108 and 111 (L108M, V111M). Murine Cav-1 forms
were recombinantly obtained as GST-fusion proteins as de-
scribed in [35]. For binding assays, 0.2μM of Glutathione S-
Transferase (GST) or GST-Cav fusion proteins (prebound to
glutathione-Sepharosebeads)wereincubatedovernightwith
equimolar amounts of morPrP or hurDpl (in a ﬁnal vol-
ume of 0.25ml), under continuous shaking at 4◦C. Proteins
bound to glutathione-Sepharose beads were eluted, washed,
and immunoblotted to detect the presence of PrP or Dpl.
In competition experiments, equimolar amounts of either
Ab ·Tg or C-20 antibodies were present during the entire in-
cubation period.
Determinationofthedissociationconstantfor
thebindingGST-CavfusionproteinsandmorPrP
Diﬀerent concentrations of morPrP (0.03–0.7μM) were in-
cubated with 0.2μM GST-Cav fusion proteins (GST-Cav 61–
101, GST-Cav 135–178, and GST-Cav FL 1–178) in the same
conditions described above. Proteins bound to glutathione-
Sepharose beads were eluted and exposed to western blot-
ting assay. The blots, stained with anti-PrP Mab 3F4, were
analyzed in transmitted light by ImageMaster VDS software
(Pharmacia Biotech, Sweden) to measure the intensity of the
bands. PrP concentration was plotted as a function of band
intensity expressed in arbitrary units.
Westernblot
For western blot analysis, denatured proteins were ﬁrst sep-
arated by a 12% SDS-PAGE, electrophoretically transferred
onto nitrocellulose and then, depending on the experiment,
incubated with the speciﬁc antibodies. Immunolabeling was
visualized by ECL procedure (Amersham, UK) and the band
intensities were measured by ImageMaster VDS software
(Pharmacia Biotech, Sweden).
Cellcultureandtransfection
Murine GN11 cells [36]w e r eg r o w na t3 7 ◦Ci n5 %C O 2 at-
mosphere in high glucose-culture medium (DMEM, Sigma,Mattia Toni et al 3
USA), supplemented with 10% heat-inactivated fetal calf
serum (FCS, Cambrex BioWhittaker, USA), 2mM L-gluta-
mine, penicillin (100U/ml), and streptomycin (100μg/ml),
as described in [37].
Cells were transiently transfected by using Lipofec-
tamine 2000 reagent (Invitrogen, USA), following manufac-
turer’sinstructions.Forcelldiﬀerentiation, phorbol ester12-
O-tetradecanoylphorbol-13-acetate (TPA) (20nM, Sigma,
USA) was added to cells soon after the transfection step, de-
pending on the experiment. For Western blot experiments,
cells were trypsinized 24 hours after transfection and re-
seeded in 25cm2 ﬂasks to obtain the same number of trans-
fected cells in each ﬂask. To assess the Erk 1/2 phospho-
rylation status, cells were serum-starved for 4 hours before
antibody-mediated ligation of PrPc. Depending on the ex-
periments, 30μM PP2 (Calbiochem, USA) was added to
the medium for 4 hours. In both immunoblotting and im-
munocytochemistry experiments, 48 hours after transfec-
tion, antibody-mediated stimulation was carried out ﬁrst by
incubating(10,20,or30min,37◦C)intactlivecellswithMab
3F4, Mab Dpl 79, or anti- β-actin Pab and then with sec-
ondary anti-mouse or anti-rabbit antibodies for additional
10–120min. (37◦C), depending on the experiment. Then,
c e l l sw e r el y z e di nl y s i sb u ﬀer (50mM Tris-HCL, pH 7.5,
2mM EDTA, 100mM NaCl, 1% Triton X100, 5mM NaF,
1mMN a3V O4,10mMβ-glycerolphosphate, and proteases
inhibitors) or ﬁxed with 4% paraformaldehyde, for western
blot or immunoﬂuorescence analysis, respectively.
Immunocytochemistry
PrPc-overexpressing GN11 cells grown on coverslips were
ﬁxed with 4% paraformaldehyde and incubated with Mab
3F4 or were stimulated by antibody-mediated ligation and
ﬁxed. Cells were permeabilized with Triton X-100 (0.1% in
phosphate buﬀer saline (PBS)) and saturated in PBS-BSA
3% for 30min. Then, cells were incubated with anti-Cav-
1 or anti-phospho Fyn Pabs (for double ﬂuorescence stain-
ing experiments) or with anti-Fyn kinase Pab (for triple ﬂu-
orescence staining experiments). After washings, cells were
incubated with anti-mouse FITC-conjugated and with anti-
rabbit Cy5- (for double staining) or Cy3- (for triple staining)
conjugated secondary antibodies. For triple immunoﬂuores-
cence staining experiments, anti-Cav-1 FITC-conjugated an-
tibody was added. Finally, slides were mounted in glycerol-
PBS medium containing 30mg/ml DABCO (Sigma, USA).
Evaluation of antibody speciﬁcity was carried out either by
omitting primary antibody or by using unspeciﬁc sera.
Confocalmicroscopy
The confocal imaging was performed on a Radiance 2000
confocal laser scanning microscope (BioRad), equipped with
a Nikon 40x, 1.4 NA objective, and with a Krypton and a Red
Diode lasers, to excite FITC (green) and Cy5 (red) ﬂuores-
cence simultaneously. Colocalization was evaluated on me-
dial optical sections using LaserPix software (BioRad) [38].
Brieﬂy, the two-dimensional scatter plot diagram of each
cell was analyzed to evaluate the spatial colocalization of the
ﬂuorochromes. For each scatter plot diagram, pixels with
highly colocalized ﬂuorochromes, that is, with intensity val-
ues greater than 150 gray levels (on a scale from 0 to 255) for
both detectors were selected to calculate the colocalization
maps and create a binary image.
Optiprepgradientﬂotation
Optiprep density gradient ﬂotation was performed as de-
scribed in Harder et al [39]. Brieﬂy, PrPc-overexpressing
TPA-diﬀerentiated cells (one conﬂuent 25cm2 ﬂask) were
lyzed (20min, 4◦C) in 200 μl of a TNE/TX buﬀer (25mM
Tris HCl (pH 7.4), 150mM NaCl, 5mM EDTA, 5mM DTT,
1%TritonX-100,andproteaseinhibitors),mixedwith400μl
of 60% Optiprep reagent (Sigma, USA), placed at the bot-
tom of an ultracentrifuge tube, and overlaid with a 600μl
step of each of 35%, 30%, 25%, 20%, and 0% Optiprep (in
TNE/TX). The gradient was spun at 200.000xg (4 hours,
4◦C), after which fractions were collected from the top of the
gradient, acid-precipitated, and analyzed by western blot.
Coimmunoprecipitationassay
In Cav-1 immunoprecipitation experiments, cells transiently
expressing the HA-tagged PrPc (one conﬂuent 25cm2 ﬂask
for each sample) were lyzed in 500μlo fab u ﬀer con-
taining 10mM Tris (pH 7.5), 150mM NaCl, 1mM EDTA,
1% Triton X-100, 0.5% NP40, 10% glycerol, and protease
inhibitors. Precleared supernatants were immunoprecipi-
tated using anti-Cav-l Pab (3μg/ml), followed by incubation
with protein A Sepharose [35]. After washings, immuno-
precipitated samples were processed by western blot to de-
tect PrPc. For sample deglycosylation, immunoprecipitates
were treated (24 hours, 37◦C) with PNGase-F (5U) (Roche
Molecular Biochemicals, Germany) [40]. For PrP immuno-
precipitation, the same protocol described above was fol-
lowed, except for the use of an anti-HA tag antibody to im-
munoprecipitate. The presence of Cav-1 in the immunopre-
cipitated samples was then assayed by immunoblotting with
anti Cav-1 Pab.
RESULTS AND DISCUSSION
InteractionbetweenPrPandCav-1
To evaluate the interaction between Cav-1 and PrPc, we
carried out in vitro binding experiments as previously de-
scribed in [35], by using four diﬀerent GST-Cav1 fusion pro-
teins and a control GST-nonfusion protein to challenge mor-
PrP. Bound PrP molecules were then immunodetected by
western blot analysis. Results clearly show that GST-CavFL
(full lenght, aa 1–178), GST-CavSD (scaﬀolding domain, aa
61–101), and GST-CavCT (C-terminal region, aa 135–178)
very eﬃciently bind morPrP. No morPrP was bound when
GST alone and GST-CavNT (N-terminal region, aa 1–81)
were challenged, indicating that the binding was speciﬁc
(Figure 1(a),1 ) .
We hypothesized that the unstructured PrP N-terminal
region [41] could represent an important binding site for4 Journal of Biomedicine and Biotechnology
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Figure 1:(a)InvitrointeractionbetweenCav-1andmorPrP.ToassessthebindingofmorPrP(23–231)andhurDpl(28–152)todiﬀerentCav-
1 domains (CavFL: full-length form (1–178); CavNT: N-terminal domain (1–81); CavSD: scaﬀolding domain (61–101); CavCT: C-terminal
domain (135–178)), prion proteins were incubated with equimolar amounts (0.2μM) of GST-Cav fusions bound to glutathione-Sepharose
beads.BoundmorPrP(1,3)andhurDpl(2)werethenvisualizedbywesternblottingwithMab3F4andpolyclonalantibodyQ55,respectively.
In 3, the binding assay was carried out in the presence of polyclonal antibodies (0.2μM) to PrP, namely, Ab ·Tg recognizing the octapeptide
region, and C-20 directed against the C-terminus. In the ﬁrst lane of (a) 1, 2, 3, 50ng morPrP or hurDpl were added as standard, while in
the second lane of (1) and (2) GST alone (ie, not fused to Cav-1) was used for the binding experiments as negative control. Data shown
are representative of three independent experiments. (b) Evaluation of Kd values of morPrP/Cav-1 complexes. Increasing concentrations of
morPrP(0.03–0.7μM)wereincubatedwithGST-Cav1fusionproteins:CavFLin1,CavSDin2,andCavCTin3,asdescribedunderMaterials
and Methods. The upper parts of (b) 1, 2, 3 show the results of western blotting experiments performed with anti-PrPc antibody (3F4). Lane
1, morPrP used as standard; lanes 2–7, 50 pmoles of GST-Cav 1 fusion proteins, CavFL in 1, CavSD in 2, and CavCT in 3, were incubated
with the indicated amounts of morPrP (ﬁnal volume 250μl). In lower parts of each panel, the concentration of morPrP used in binding
assays was plotted as a function of band intensity, which was quantiﬁed using ImageMaster VDS Software (Pharmacia Biotech, Sweden). The
dissociation constants calculated from each plot ranged from 8 to 9 ×108 M
−1. The data are representative of two independent experiments.
Cav-1. This region is characterized by the presence of an
octapeptide sequence PHGGGWGQ repeated ﬁve times in
tandem and involved in the binding of copper ions [9]. To
demonstrate our hypothesis, we ﬁrst evaluated whether Dpl
protein binds to Cav-1. Dpl is a protein which shows high
sequence homology with the C-terminus of PrPc but lacksMattia Toni et al 5
the N-terminal octapeptide region [42, 43]. To this end, we
probed the hurDpl under the same conditions used for mor-
PrP binding to Cav-1. However, contrary to morPrP, hurDpl
showed no interaction with Cav-1 (Figure 1(a),2 ) .
More details about the PrPc N-terminal sites involved in
the binding to Cav-1 were obtained using a polyclonal anti-
bodyAb ·Tg.Thisantibodyspeciﬁcallyrecognizedtwonon-
adjacent octapeptide repeats (57–65 and 81–89) since a sub-
stitution G/S was suﬃcient to abrogate recognition. The use
of Ab ·Tg antibody almost completely blocked the morPrP
bindingtoGST-CavSD(61–101),whileanantibodydirected
against a PrP C-terminal epitope had a much lower eﬀect
(Figure 1(a), 3). Taken together, these results indicate that
the octapeptide repeats could represent a PrP binding site for
Cav-1.
The results of experiments aimed at evaluating the
PrP/Cav-1 binding aﬃnity constants are shown in Fig-
ure 1(b). Amounts of morPrP ranging from 0.03μMt o
0.7μM were incubated with diﬀerent GST-caveolin fusion
proteins, as described under Material and Methods. Bands
intensity in western blots was quantiﬁed by densitometry.
Plots representing the binding of GST-CavFL (1–178), GST-
CavSD (61–101), and GST-CavCT (135–178) are shown in
panels B1, B2, and B3, respectively. Evaluation of dissocia-
tionconstant(Kd)byreciprocalplotsshowedthatKdranged
from 8 to 9 ×108 M−1 for all the three fusion proteins. Since
no binding was observed using GST alone or GST CavNT
fusion protein, it appears that unspeciﬁc binding is not oc-
curring in our experimental conditions.
To determine if the interaction between PrP and Cav-1
observed in vitro occurred also in a physiological environ-
ment and if this interaction had any eﬀects on signal trans-
duction, we used, as cellular model, a cell line of immortal-
ized luteinizing hormone-releasing hormone (LHRH) neu-
rons that naturally expresses high levels of Cav-1 [44]a n d
that was prone to be transiently transfected with high ef-
ﬁciency with a plasmid encoding the HA tagged morPrP
protein.
In PrPc-overexpressing GN11 cells, PrPc appears uni-
formly distributed on the plasma membrane (Figure 2(a),1 )
and shows a low colocalization level with Cav-1 (Figure 2(a),
3 and 4). Given that it has been shown that GPI-anchored
proteins residing in rafts translocate to caveolae following
clustering induced by antibody-mediated cross-linki [21,
39], we stimulated live PrPc-overexpressing GN11 cells with
anti-PrPc antibody (30min) and with FITC-conjugated sec-
ondary antibody (30min), observing that PrPc clusters in
plasma membrane microdomains (in Figure 2(a),5a n d9 ,
arrowheads indicate the clusters of PrPc) rich in Cav-1
(Figure 2(a), 6 and 10). In these clusters we detected a high
level of colocalization between PrPc and Cav-1 (Figure 2(a),
8 and 12).
In order to obtain a neuronal environment closer to that
inwhichPrPcoperatesphysiologically,wetreatedGN11cells
with TPA, an inducer of cell diﬀerentiation (Figure 2(b),1 –
4). Analysis of PrPc-overexpressing GN11 cells treated with
TPA has shown an increase in the co-localization level be-
tween PrPc and Cav-1 (Figure 2(b), 3 and 4). Since in vitro
experiments (Figure 1(a), 2) have shown an incapacity of
Cav-1 to bind Dpl and since Dpl is a surface protein ex-
posed to the exoplasmic space through a GPI-anchor like
PrPc [45], confocal microscopy analyses were performed on
GN11cellsoverexpressingtheDplproteindiﬀerentiatedwith
TPA (Figure 2(b), 5–8). When Dpl was cross-linked using a
speciﬁc antibody, colocalization with Cav-1 at plasma mem-
brane level was undetectable (Figure 2(b), 7–8) conﬁrming a
diﬀerent behavior between PrPc and Dpl and suggesting that
Doppel, although located through a GPI anchor in the same
microdomains of PrPc, could be unable to participate in
the transduction of survival signals, thus favoring conditions
slowlyleadingtoapoptosis.Forexample,failureofDoppelto
bind Cav-1 could impair Fyn kinase recruitment due to PrPc
activation [13], thus altering the normal fate of cell diﬀer-
entiation occurring during brain development. Our results
may also help to explain why the reintroduction of a wild-
type Prnp gene, in PrPc 0/0 mice expressing Doppel protein
in the brain, rescues them from neurodegeneration [46]. In
fact, PrPc, having a higher aﬃnity for transducing machin-
ery, may displace Doppel protein and trigger survival signals.
Evidence supporting a role of PrPc in regulating cell prolifer-
ation,diﬀerentiation,andsurvivalhasbeenrecentlycollected
bySatohandcoworkers[47],whocomparedthegeneexpres-
sionproﬁleinﬁbroblastcelllinesderivedfromPrPc-deﬁcient
mice(Prnp0/0)andfromPrPwild-typemice.Theyobserved
that the disruption of Prnp gene resulted in an aberrant reg-
ulation of a battery of genes important for cell proliferation,
diﬀerentiation, and survival, including those located in the
Ras and Rac signaling pathways. Moreover, Kuwahara and
coworkers [48]observedthatthereintroductionofwild-type
Prnp gene prevented apoptosis in hippocampal cells derived
from Prnp 0/0 mice and cultured under serum-free condi-
tions.
To further conﬁrm the PrPc/Cav-1 colocalization, ex-
periments of ﬂotation in density gradient were performed.
Extracting cells with Triton X-100 at 4◦Ca n df r a c t i o n a t -
ing the insoluble material by OptiPrep or sucrose-gradient
centrifugation are considered a stringent criterion to es-
tablish whether a protein is present in detergent-insoluble
glycolipid-rich domains (DIGs) and colocalizes with Cav-1
[49]. Nevertheless, it is diﬃcult to obtain a separation be-
tween rafts and caveolae. We applied this procedure to GN11
cells, transiently transfected with Prnp or Prnd,a n de v a l -
uated PrPc, Cav-1, and Dpl distribution by western blot.
Results obtained (Figure 3(a)) show a marked colocaliza-
tion between PrPc and Cav-1 in low-density gradient frac-
tions (Figure 3(a), 1 and 2, resp.). Interestingly, Dpl protein
(Figure 3(a),3),evenifitisaGPI-linkedproteintoo,showsa
wide distribution in most fractions of the gradient that does
not correlate with Cav-1 distribution.
Mouillet-Richard et al [13] detected the presence of Cav-
1 in immunoprecipitated samples obtained by using an anti-
PrPc antibody, particularly when neuronal cells were in-
duced to diﬀerentiate. We proposed to conﬁrm these re-
sults in GN11 neuronal cells transiently transfected with
murine Prnpgene. Reciprocal coimmunoprecipitation ex-
periments in HA tagged-PrPc-overexpressing GN11 cells6 Journal of Biomedicine and Biotechnology
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.
were performed to further conﬁrm PrPc-Cav1 interac-
tion (Figure 3(b)). We found that anti-HA-tag antibodies
coimmunoprecipitate Cav-1 (Figure 3(b), lane 2) and, re-
ciprocally, that anti-Cav-1 antibodies coimmunoprecipitate
PrP (Figure 3(b), lanes 3 and 4) in cells stimulated by
anti-PrPc antibody- (30min) and by secondary antibody-
(30min) mediated ligation. After deglycosylation treatment
(Figure 3(b), lane 4), the smear typical of PrPc was resolved
in a single band of 27 kDa. Interestingly, the sensitivity of
western blot detection did not permit to reveal Cav-1 in
coimmunoprecipitates of unstimulated cells (lane 1) con-
ﬁrmingtheimportanceofantibodystimulationinPrPc/Cav-
1 interaction.
To follow the fate of PrPc/Cav-1 complexes, a time-
course of PrPc and Cav-1 distributions after anti-PrPc
antibody-mediated stimulation was analyzed by confocal
microscopy in living GN11 cells overexpressing PrPc. In
Figure 4 it is shown that the PrPc/Cav-1 colocalized sig-
nal, at plasma membrane level, was evident after 60min of
anti-PrPc antibody-mediated stimulation (A–D). However,
after 90min, PrPc was prominent in the intracellular space
and only a few spots of colocalized signals were present at
plasma membrane level (E–H). After 150min, PrPc became
almost exclusively intracellular (I) while Cav-1 distribution
appeared unchanged (J), and colocalization signals were un-
detectable (K), (L). It is likely that when caveolae are de-
tachedfromsurfacemembranethedissociationofPrPc/Cav-
1 complexes takes place. However, western blotting analysis
of PrPc at diﬀerent times (M, N, and O) showed that no
degradation of PrPc, even after 2 h, was evident. Moreover,
the extent of PrPc glycosylation was unchanged.
InvolvementofPrPcinsignaltransduction
Since we hypothesized a role of PrPc clustering and of PrPc-
Cv 1 colocalization in signal transduction, we performed
confocal microscopy experiments to assess if Fyn kinase re-
sponds, in someway, to an anti-PrP antibody-mediated stim-
ulation (Figure 4). Biedi and collaborators demonstrated
the recruitment of Fyn kinase from cytoplasm to caveo-
lae in ﬁbroblasts overexpressing wild-type IGF-IR stimu-
lated by IGF-I [50]. In a similar way, after the stimula-
tion of PrPc-overexpressing GN11 cells with anti-PrPc an-
tibody (30min) and with secondary antibody (30min) to
induce PrPc patching, we observed the shift of Fyn kinase
from the cytoplasm towards the membrane (in Figure 5(c),
compare the Fyn distribution in a transfected cell sub-
jected to the stimulation (arrowhead) with an untrans-
fected cell not subjected to the stimulation (arrow)). Af-
ter the antibody-mediated stimulation, we revealed a high8 Journal of Biomedicine and Biotechnology
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colocalization between PrP and Cav-1 (panel D) and be-
tween PrP and Fyn kinase (panel E) on the plasma mem-
brane. It was previously reported that PrPc and Fyn ki-
nase do not colocalize in neurons; however in those ex-
periments cells were not stimulated by anti-PrPc antibody
[51].
To evaluate if the Fyn kinase recruited in the clusters
of PrPc/Cav-1 was activated, we performed confocal im-
munoﬂuorescence experiments by using a speciﬁc antibody
that recognizes the active form of Fyn kinase phosphory-
lated on Tyr 416 (Figure 6). In GN11 cells that do not ex-
press PrPc, the signal of active Fyn kinase is low and wide
dispersed in the cytoplasm (data not shown). On the con-
trary, in PrP-overexpressing GN11 cells we detected a low
activation of Fyn kinase on plasma membrane (Figure 6,B
and F). Following anti-PrPc antibody-mediated stimulation
(20min), an increased level of active Fyn kinase located in
the correspondence of PrPc clusters was detected (J, N, ar-
rowheads indicate PrPc clusters). After 40min of antibody
stimulation, the signal of active Fyn kinase was weaker and
after 60min it was no more detectable (data not shown).
Taken together, these data show that following anti-PrPc an-
tibody mediated stimulation, PrPc patches on the plasma
membrane in clusters in which Fyn kinase is recruited and
activated.
It has been reported that activated Fyn kinase can trans-
duceasignalcascadethroughErk1/2kinase[52].Toevaluate
if in GN11 cells the activation of PrPc by antibody-mediated
ligation triggers a signal transduction pathway through Erk
1/2, we perform the experiments reported in Figure 7.T h e
incubation of PrP-overexpressing GN11 cells with anti-PrPc
(3F4) and secondary antibody for a total time of 20 and
40min caused the activation of Erk 1/2 kinase by induc-
ing their phosphorylation (lanes 3 and 4), while the incuba-
tion with unrelated antibodies had no eﬀects (lane 5). Erk1/2
phosphorylation levels did not increase if cells were previ-
ously treated with the Fyn kinase inhibitor PP2 (lane 6). This
result suggests that the activation of Fyn kinase following
anti-PrPc antibody-mediated stimulation, observed by con-
focal microscopy, may trigger a downstream activation ofMattia Toni et al 9
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Figure 5: Fyn kinase shift from cytoplasm into membrane caveolae. Live GN11 cells PrPc transiently transfected were incubated with anti-
PrP Mab 3F4 (30min), followed by secondary Cy3-conjugated antibody (30min), to allow antibody-mediated ligation (and visualization)
of PrPc B. After ﬁxing and permeabilizing cells, anti-Fyn kinase polyclonal antibody and secondary Cy5-conjugated antibody were added
to visualize Fyn kinase distribution (C). Finally, anti-caveolin1 FITC-conjugated antibody was added to visualize Cav-1 distribution (A).
The superposition of green (Cav-1 in D; Fyn kinase in E) and red (PrPc in D and E) signals provided the images shown in D and E.
Arrowheads show the PrPc-overexpressing cells and arrows do not indicate transfected cells. Images (A–E) result from integrating diﬀerent
optical sections.. Bar = 7.5μm.
Erk 1/2 signaling pathway. Our data, obtained in a neuronal
model expressing Cav-1, conﬁrm that PrPc triggers a Fyn ki-
nase and Erk 1/2 signaling pathway as previously reported
[15, 31, 32, 53].
To obtain this activation, PrPc and Fyn kinase need to
co-localize in caveolae: PrPc clusters on the plasma mem-
brane following the antibody (or other putative physiolog-
ical ligands) binding, and Fyn kinase moves from cytoplasm
to caveolae.
In order to demonstrate the essential role of Cav-1 in
the PrPc-Fyn-Erk 1/2 signaling pathway, we down-regulated
or misallocated caveolin 1 by using anti-Cav-1 antisense
oligonucleotides and Filipin III, respectively. The aim was to
obtain an experimental condition in which the absence of
Cav-1 could prevent the activation of the transduction cas-
cade triggered by PrPc clustering. However, these treatments
in GN11 cells did not permit to obtain clear results as they
caused a strong increase of Erk 1/2 phosphorylation level
(datanotshown).TheabilityofCav-1todirectlyinhibitsErk
1/2 activation has been reported in other experimental mod-
els [25, 26]. Moreover, the hyperactivation of Erk 1/2 signal-
i n gw a sr e p o rt e di nC a v - 1( −/−) null mouse cells and tissues
[28, 29, 54], and in NIH-3T3 cells in which Cav-1 was down-
regulated by antisense [27]. The inhibitory eﬀect of Cav-1 on
Erk1/2mayexplainwhy,inourcellularmodel,itissohardto
demonstrate the direct involvement of Cav-1 in signal trans-
duction events triggered by PrPc stimulation.
The data reported here conﬁrm the involvement of PrPc
in signal transduction events through Fyn and Erk 1/2 ki-
nase and demonstrate caveolae to be the physical place
in which this signal cascade switches on. In vitro binding
experiments’s results suggest that a physical interaction be-
tween PrPc and Cav-1 could be involved in these signaling
events, even if this is unlikely considering the nowadays-
accepted location of PrPc and Cav-1 on the opposite side of
the plasma membrane.10 Journal of Biomedicine and Biotechnology
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PrPc antibody. GN11 cells were transfected with empty HA-plasmid
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antibody (a) and anti-β-actin antibody (b). Band intensities were
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